Earnings Report Preview: ImmunoPrecise Antibodies Ltd.

The report highlights that ImmunoPrecise Antibodies Ltd. is set to report earnings with a consensus EPS forecast of -$0.09, indicating an 18.18% increase from last year, despite missing previous estimates significantly.

Date: 14-09-2024

AI Rating: 4

The upcoming earnings report for ImmunoPrecise Antibodies Ltd. (IPA) indicates a projected earnings per share (EPS) of -$0.09 for the quarter ending July 31, 2024. This forecast suggests an 18.18% increase compared to the same quarter last year, which may be perceived positively despite the negative EPS figure.

However, it's important to note that IPA missed the previous EPS consensus by a staggering 420% in the 2nd quarter of 2024. Such a substantial miss can negatively impact investor sentiment and confidence in the company's ability to meet future expectations.

Furthermore, the Price to Earnings (P/E) ratio for IPA in 2025 is noted as -2.56, significantly lower than the industry average of 21.10. A negative P/E ratio indicates that the company is generating losses rather than profits, which can be a red flag for investors looking for stable growth.

Overall, the combination of a forecasted EPS that still remains negative despite a year-over-year increase, coupled with the alarming prior earnings miss and a deeply negative P/E ratio, could lead to downward pressure on the stock price in the upcoming days.

Stocks: IPA